Accepted abstracts include discussion of care pathways and outcomes following atrial fibrillation diagnosis, advancements in integrated PFA solutions and REAL-AF Registry insights, among other data
Irvine, CA – April 24, 2025 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia care, today announced data from 22 company sponsored or funded studies will be presented at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego from April 24-27. The studies span Johnson & Johnson MedTech’s comprehensive portfolio of electrophysiology solutions and include discussion of treatment strategies for newly diagnosed patients, and utilization of a growing portfolio of pulsed field ablation technologies, among others.
“As rising clinical demand accelerates the need for safe, effective and efficient cardiac ablation solutions, Johnson & Johnson MedTech is proud to advance evidence-driven innovation that meets the evolving needs of physicians and patients worldwide,” said Jasmina Brooks, President, Electrophysiology, Johnson & Johnson MedTech. “At this year’s HRS Annual Meeting, we are excited to bring forward compelling data that reinforces our commitment in electrophysiology, and to support collaborative efforts such as the REAL-AF Registry and the Patient Care Pathways and Outcomes study to help optimize treatment strategies. The Patient Care Pathways and Outcomes study in particular underscores the continued importance of guideline adherence and broad dissemination to drive better patient outcomes. We look forward to engaging the EP community in meaningful dialogue that fuels innovation and enhances the management of AFib.”
In addition to data presentations, Johnson & Johnson MedTech will support a variety of educational programs, in-booth presentations and training opportunities for attendees throughout the meeting. Also at the meeting, the company will honor the 2025 Will Webster Lectureship Award recipient. Established in memory of Will Webster, a company co-founder, this prestigious award recognizes transformative contributions to the field of cardiac electrophysiology.
Highlights of data being presented include:
Late-Breaking Presentation: Safety, Efficacy and PVI Durability of a Contact Force-Sensing Large-Tip Focal Pulsed Field Ablation Catheter Integrated With 3D Mapping to Treat Paroxysmal Atrial Fibrillation: First-in-Human Omny-IRE 3-Month Results. Room 20BCD – SDCC. April 25, 12:00 p.m. PST, by Dr. Mattias Duytschaever, St. Jan Hospital, Brugge-Oostende, Belgium.i
Oral Presentation: Predicting Lesion Depth During Pulsed Field Ablation: Prospective Validation of a Novel Ablation Index Based on Contact Force and Number of Applications in a Swine Beating Heart Model. AB-499634-003. Oral Abstract Hub 1 - Sails Pavilion – SDCC. April 24, 4:24 p.m. PST, by Dr. Hiroshi Nakagawa, Cleveland Clinic.ii
Poster Presentation: Real-world Data of Sex Differences in Ablation Strategy and Outcomes for Paroxysmal Atrial Fibrillation: Insights from the REAL-AF Registry. PO-02-018, Abstract Pavilion - Exhibit Hall – SDCC. April 25, 1p.m. PST, by Dr. Zhuxin Zhang, Brigham and Women's Hospital.iii
Oral Presentation: Patient Care Pathways and Outcomes Following Newly Diagnosed Atrial Fibrillation. QI-499658-003. Oral Abstract Hub 4 - Sails Pavilion, SDCC. April 26, 4:18 p.m. PST, by Dr. T Jared Bunch, University of Utah School of Medicine.iv
Poster Presentation: Evaluating Safety Profile and Learning Curve with a Pulsed Field Ablation Variable Loop Circular Catheter in Procedures for AF: Observations from a Prospective, Multicenter, Postmarket Clinical Trial. PO-07-216. Abstract Pavilion - Exhibit Hall, SDCC. April 27, 9:00 a.m. PST, by Dr. Francis Bessiere, Hopital Cardiologique Louis Pradel.v
The data presented at HRS build on clinical evidence shared by Johnson & Johnson MedTech in recent months, including 12-month results from the SmartfIRE clinical trial presented at the European Heart Rhythm Association (EHRA) Annual Meeting.1 The robust set of abstracts to be presented at HRS further demonstrates the company's commitment to advancing the next wave of innovation in electrophysiology to fuel improved treatment outcomes.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circular restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com and connect on LinkedIn and X, formerly Twitter.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at thenext.jnjmedtech.com. Biosense Webster, Inc. is part of Johnson & Johnson MedTech.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the OMNYPULSE™ Platform clinical trials, VARIPULSE™ Platform, CARTO™ 3 System, and Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of healthcare products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com or on request from Johnson & Johnson. Neither Biosense Webster, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
Media Contacts:
Lindsey Diaz-MacInnis
[email protected]
Kristina Kauffman
[email protected]
i. Dr. Duytschaever served as a study investigator and as a consultant for Johnson & Johnson MedTech. Dr. Duytschaever was not compensated for this authorship contribution.
ii. Dr. Nakagawa served as a study investigator and as a consultant for Johnson & Johnson MedTech. Dr. Nakagawa was not compensated for this authorship contribution. iii. Dr. Zhang served as a study investigator and as a consultant for Johnson & Johnson MedTech. Dr. Zhang was not compensated for this authorship contribution.
iv. Dr. Bunch served as a study investigator and as a consultant for Johnson & Johnson MedTech. Dr. Bunch was not compensated for this authorship contribution.
v. Dr. Bessiere served as a study investigator and as a consultant for Johnson & Johnson MedTech. Francis Bessiere was not compensated for this authorship contribution.
- De Potter T, Scherr D, Pürerfellner H, et al. Safety, effectiveness, and healthcare benefits of a dual energy focal ablation technology to treat paroxysmal
atrial fibrillation: SmartfIRE 12-month results. Presented at EHRA 2025; March 31, 2025; Vienna, Austria. Pending formal publication.
© Johnson & Johnson and its affiliates 2025. All rights reserved. US_ELP_ALEL_399651